Knowledge Library
Updated methods for single use components
Leachables from single use systems can impact your drug product. This presentation will help guide you through those risks and present some options for test methods.
Contract Pharma interview with SVP and global head of advanced therapies talks about cell and gene therapy market trends
WuXi AppTec’s Felix Hsu on ‘Make vs Buy’ Decisions At BIO 2019, Contract Pharma had a chance to talk with WuXi AppTec’s Felix Hsu, SVP and Global Head of Advanced Therapies, about “Make vs Buy” decisions, as well as cell and gene therapy market trends.
Lenti non-settled suspension harvest clarification process development
VIEW ON-DEMAND WEBINAR This webcast features: Stephen Tottey, PhD, Associate Principal Scientist, Process and Technology Development, Wuxi Advanced Therapies and John Taylor, Process Development Scientist, MilliporeSigma. Clarification of non-settled Lenti suspension harvest can be challenging due to high level of impurities in the feed stream, physical characteristics of the vector, limited filter choices, and low …Read More >
Considerations for development of a platform lentivirus harvest clarification process for cell and gene therapy
New therapies, medicines and cutting-edge technologies have enabled the production of next generation treatments that improve patient care, simplify administration and increase the availability of life changing medicines. One of the new technologies emerging in the biotech manufacturing market is the use of viral vectors for cell and gene therapy. One commonly used viral vector …Read More >
3 business challenges from the CDMO’s perspective
Felix Hsu, SVP and Global Head of WuXi Advanced Therapies and Erin Harris, Editor in Chief for Cell & Gene had a great conversation around the CDMOs perspective on manufacturing. Click to learn more about 3 Business Challenges from the CDMO’s Perspective. By Erin Harris, Editor-in-Chief of cellandgene.com Copyright © 1996-2019 VertMarkets, Inc. All Rights Reserved.